We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase 2 Study of Carboplatin, Docetaxel, and Bevacizumab as Frontline Treatment for Advanced Nonsmall – Cell Lung Cancer.
- Authors
William, Jr., William N.; Kies, Merrill S.; Fossella, Frank V.; Liu, Diane D.; Gladish, Gregory; Tse, Warner H.; Lee, J. Jack; Waun K. Hong; Lippman, Scott M.; Kim, Edward S.
- Abstract
The article discusses a study which determines the effectiveness of the combined carboplatin, bevacizumab and docetaxel in the treatment of patients with nonsquamous nonsmall-cell lung cancer (NSCLC). The study uses 40 patients who were treated with 6 cycles of carboplatin, bevacizumab and docetaxel every 21 days. The results demonstrate that the combination of carboplatin, bevacizumab and docetaxel is an effective and a feasible treatment for patients with advanced, squamous NSCLC.
- Subjects
LUNG cancer patients; CANCER treatment; SQUAMOUS cell carcinoma; BEVACIZUMAB; DOCETAXEL; ANTINEOPLASTIC agents
- Publication
Cancer (0008543X), 2010, Vol 116, Issue 10, p2401
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.24996